News und Analysen
4 Dividend Aristocrats Trading at a Discount
The first quarter of the year was a success for investors. The overall market (NYSE: SPY) surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI. The
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflow of investment dollars not seen since the last wave of the business cycle. This
MarketBeat Week in Review – 5/22 - 5/26
Two competing stories are fighting for investors’ attention. The bulls are trying to push the market higher in expectations of a resolution to the debt ceiling standoff. But any excitement is being
Centene Reaffirms Guidance, But Is it Too Late?
Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through
Is Cigna Group the Nation's Best-Run Health Insurance Company?
Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the
AbbVie Tracking for New Highs in 2024
Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain
Abbott Laboratories Outlook is Healthy: Buy the Dip
Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market
Undervalued UnitedHealth Group Won’t Be For Long
UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside
Biotech Sector Nears Breakout: Will it Outperform in Q2?
The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.
The bullish
7 Stocks That Will Drive the Weight Loss Drugs Market
The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems. Pharmaceutical companies are
4 Oversold Large Cap Stocks Yielding High Dividends
As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI, the murmurs of potential interest rate cuts by the Federal Reserve
Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290% mit Novo-Nordisk ($NVO)
Eilt: Völlig neue Krebsbehandlung - Hautkrebs vollständig geheilt. Diesen Biotech Hot Stock jetzt kaufen nach 9.290%
13.03.24 08:02
London (www.aktiencheck.de, Anzeige)
Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)
Eilt: Studie für völlig neue Krebsbehandlung genehmigt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX)
12.03.24
London (www.aktiencheck.de, Anzeige)
Link
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. Neuer 797% Biotech Hot Stock nach 15.973% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB).
Sensationelle Studienergebnisse - Hautkrebs vollständig geheilt. 797% Biotech Hot Stock nach 10.996% mit Pfizer ($PFE)
11.03.24 08:02
London (www.aktiencheck.de, Anzeige)
Eilt: Hautkrebs vollständig geheilt - Blockbuster gegen Hautkrebs. Neuer 797% Biotech Aktientip nach 15.973% mit BioNTech ($BNTX)
Eilt: Hautkrebs vollständig geheilt - Blockbuster gegen Hautkrebs. Neuer 797% Biotech Aktientip nach 15973% mit BioNTech
08.03.24 08:03
London (www.aktiencheck.de, Anzeige)
Eilt: Durchbruch in der Krebsforschung - Hautkrebs vollständig geheilt. 661% Biotech Hot Stock nach 15.973% mit Biotech ($BNTX)
Eilt: Durchbruch in der Krebsforschung - Hautkrebs vollständig geheilt. 661% Biotech Hot Stock nach 134.452% mit Biogen
07.03.24 08:02
London (www.aktiencheck.de , Anzeige)
Biotech Hot Stock 2024: Erstklassige Studienergebnisse - Hautkrebs vollständig geheilt. Diese Biotech-Aktie jetzt kaufen nach 15.973% mit Biotech ($BNTX)
Biotech Hot Stock 2024: Erstklassige Studienergebnisse - Hautkrebs vollständig geheilt. Diese Biotech-Aktie jetzt kaufen
06.03.24 08:02
London (www.aktiencheck.de, Anzeige)
Is UnitedHealth Group Stock a Strong Buy or a Falling Knife?
UnitedHealth Group Inc. (NYSE: UNH) has given up almost all of its 12-month gains in the last week after two unrelated incidents have rocked the company. At the close of trading on March 1, 2024
Eilt: 95% weniger Medikamente - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: 95% weniger Medikamente - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Hot Stock nach 9.290% mit Novo-Nordisk
05.03.24
London (www.aktiencheck.de, Anzeige)
Eilt: 100 mal wirksamer gegen Krebs - Großinvestoren unmittelbar vor Einstieg. Neuer 503% Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: 100 mal wirksamer gegen Krebs - Großinvestoren unmittelbar vor Einstieg. Neuer 503% Biotech Hot Stock nach 15.973%
04.03.24 08:02
London (www.aktiencheck.de , Anzeige)
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. Neuer 503% Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Sensationelle Studienergebnisse - 100 mal wirksamer gegen Krebs. 503% Biotech Aktientip nach 134.452% mit Biogen
01.03.24 08:03
London (www.aktiencheck.de, Anzeige)